1. Home
  2. BGM vs ESLA Comparison

BGM vs ESLA Comparison

Compare BGM & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGM
  • ESLA
  • Stock Information
  • Founded
  • BGM 2019
  • ESLA 2021
  • Country
  • BGM China
  • ESLA United States
  • Employees
  • BGM N/A
  • ESLA N/A
  • Industry
  • BGM
  • ESLA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BGM
  • ESLA Health Care
  • Exchange
  • BGM NYSE
  • ESLA Nasdaq
  • Market Cap
  • BGM 50.6M
  • ESLA 41.6M
  • IPO Year
  • BGM 2021
  • ESLA N/A
  • Fundamental
  • Price
  • BGM $8.72
  • ESLA $1.13
  • Analyst Decision
  • BGM
  • ESLA
  • Analyst Count
  • BGM 0
  • ESLA 0
  • Target Price
  • BGM N/A
  • ESLA N/A
  • AVG Volume (30 Days)
  • BGM 45.8K
  • ESLA 59.2K
  • Earning Date
  • BGM 02-13-2025
  • ESLA 02-12-2025
  • Dividend Yield
  • BGM N/A
  • ESLA N/A
  • EPS Growth
  • BGM N/A
  • ESLA N/A
  • EPS
  • BGM N/A
  • ESLA N/A
  • Revenue
  • BGM $29,870,461.00
  • ESLA N/A
  • Revenue This Year
  • BGM N/A
  • ESLA N/A
  • Revenue Next Year
  • BGM N/A
  • ESLA N/A
  • P/E Ratio
  • BGM N/A
  • ESLA N/A
  • Revenue Growth
  • BGM N/A
  • ESLA N/A
  • 52 Week Low
  • BGM $1.78
  • ESLA $0.63
  • 52 Week High
  • BGM $11.67
  • ESLA $3.23
  • Technical
  • Relative Strength Index (RSI)
  • BGM 58.56
  • ESLA 50.41
  • Support Level
  • BGM $8.15
  • ESLA $1.03
  • Resistance Level
  • BGM $8.80
  • ESLA $1.41
  • Average True Range (ATR)
  • BGM 0.80
  • ESLA 0.21
  • MACD
  • BGM -0.00
  • ESLA -0.01
  • Stochastic Oscillator
  • BGM 21.41
  • ESLA 21.98

About BGM QILIAN INTERNATIONAL HLDG GROUP LTD

BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium.

About ESLA Estrella Immunopharma Inc.

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Share on Social Networks: